Targeted therapy for non-small-cell lung cancer

Past, present and future

Research output: Contribution to journalArticle

Abstract

Therapy for advanced non-small-cell lung cancer has developed significantly with new awareness of histologic subtype as an important factor in guiding treatment and the development of targeted agents for molecular subgroups harboring critical mutations that spur on cancer growth. In this comprehensive review, we look back at developments in targeted therapy for advanced non-small-cell lung cancer, reviewing in detail efforts, both successful and in some cases less so, to target EGFR, VEGF and ALK. This review provides an overview of where the field stands at present and the areas we feel are most likely to provide challenges and potential successes in the next 5 years including immune checkpoint inhibition, epigenetic therapy and driver mutation targeting.

Original languageEnglish (US)
Pages (from-to)745-758
Number of pages14
JournalExpert Review of Anticancer Therapy
Volume13
Issue number6
DOIs
StatePublished - Jun 2013

Fingerprint

Non-Small Cell Lung Carcinoma
Mutation
Epigenomics
Vascular Endothelial Growth Factor A
Therapeutics
Growth
Neoplasms

Keywords

  • PD1
  • targeted therapy
  • VEGF

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Targeted therapy for non-small-cell lung cancer : Past, present and future. / Forde, Patrick; Ettinger, David S.

In: Expert Review of Anticancer Therapy, Vol. 13, No. 6, 06.2013, p. 745-758.

Research output: Contribution to journalArticle

@article{0db52cd02da64191aa8d394b412a1ebb,
title = "Targeted therapy for non-small-cell lung cancer: Past, present and future",
abstract = "Therapy for advanced non-small-cell lung cancer has developed significantly with new awareness of histologic subtype as an important factor in guiding treatment and the development of targeted agents for molecular subgroups harboring critical mutations that spur on cancer growth. In this comprehensive review, we look back at developments in targeted therapy for advanced non-small-cell lung cancer, reviewing in detail efforts, both successful and in some cases less so, to target EGFR, VEGF and ALK. This review provides an overview of where the field stands at present and the areas we feel are most likely to provide challenges and potential successes in the next 5 years including immune checkpoint inhibition, epigenetic therapy and driver mutation targeting.",
keywords = "PD1, targeted therapy, VEGF",
author = "Patrick Forde and Ettinger, {David S}",
year = "2013",
month = "6",
doi = "10.1586/era.13.47",
language = "English (US)",
volume = "13",
pages = "745--758",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Targeted therapy for non-small-cell lung cancer

T2 - Past, present and future

AU - Forde, Patrick

AU - Ettinger, David S

PY - 2013/6

Y1 - 2013/6

N2 - Therapy for advanced non-small-cell lung cancer has developed significantly with new awareness of histologic subtype as an important factor in guiding treatment and the development of targeted agents for molecular subgroups harboring critical mutations that spur on cancer growth. In this comprehensive review, we look back at developments in targeted therapy for advanced non-small-cell lung cancer, reviewing in detail efforts, both successful and in some cases less so, to target EGFR, VEGF and ALK. This review provides an overview of where the field stands at present and the areas we feel are most likely to provide challenges and potential successes in the next 5 years including immune checkpoint inhibition, epigenetic therapy and driver mutation targeting.

AB - Therapy for advanced non-small-cell lung cancer has developed significantly with new awareness of histologic subtype as an important factor in guiding treatment and the development of targeted agents for molecular subgroups harboring critical mutations that spur on cancer growth. In this comprehensive review, we look back at developments in targeted therapy for advanced non-small-cell lung cancer, reviewing in detail efforts, both successful and in some cases less so, to target EGFR, VEGF and ALK. This review provides an overview of where the field stands at present and the areas we feel are most likely to provide challenges and potential successes in the next 5 years including immune checkpoint inhibition, epigenetic therapy and driver mutation targeting.

KW - PD1

KW - targeted therapy

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84879379247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879379247&partnerID=8YFLogxK

U2 - 10.1586/era.13.47

DO - 10.1586/era.13.47

M3 - Article

VL - 13

SP - 745

EP - 758

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 6

ER -